A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

Phase 3

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Other: Placebo
Drug: Atezolizumab

Registration Number: NCT03024996

Lead Sponsor: Hoffmann-La Roche

Brief Summary: This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 778

Inclusion Criteria

ECOG performance status of less than or equal to (</=) 1
Pathologically confirmed RCC with a component of either clear cell histology or sarcomatoid histology that has not been previously treated in the adjuvant or neoadjuvant setting and classified as being at high risk of RCC recurrence
Radical or partial nephrectomy with lymphadenectomy in select participants
Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization. Confirmation of disease-free status will be assessed by an independent central radiologic review of imaging data.
Absence of brain metastasis, as confirmed by a negative CT with contrast or magnetic resonance imaging (MRI) scan of the brain, no more than 4 weeks prior to randomization. Applicable only to metastasectomy participants
Full recovery from nephrectomy or metastasectomy within 12 weeks from randomization following surgery

Exclusion Criteria

Bilateral synchronous tumors with inheritable forms of RCC including von Hippel-Lindau
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days or five half-lives of the investigational agent, whichever is longer, prior to enrollment
Malignancies other than RCC within 5 years prior to Cycle 1, Day 1
History of autoimmune disease
Participants with prior allogeneic stem cell or solid organ transplantation
History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
Positive test for HIV
Participants with active hepatitis B or hepatitis C
Active tuberculosis
Severe infections within 4 weeks prior to randomization including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Prior treatment with cluster of differentiation (CD)137 agonists, anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), or anti-programmed death-ligand 1 (anti-PD-L1) therapeutic antibody or pathway-targeting agents
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to randomization
Treatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to randomization or anticipated need for systemic immunosuppressive medications during the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
Atezolizumab	Atezolizumab	Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).

Primary Outcome Measures

Name	Time	Method
Investigator-assessed Disease-Free Survival (DFS)	From baseline up to first occurence of event by investigator assessment (up to approximately 64 months)	Investigator-assessed DFS, defined as the time from randomization to death from any cause or the first documented recurrence assessed by investigator, whichever occurred first. Recurrence was defined as any of the following: Local recurrence of renal cell carcinoma (RCC), new primary RCC, or distant metastasis of RCC. Investigator-assessed DFS was analyzed similarly to the analysis of IRF-assessed DFS.

Secondary Outcome Measures

Name	Time	Method
Independent Review Facility (IRF)-Assessed DFS	From baseline until first documented recurrence event (up to approximately 64 months)	IRF-assessed DFS was defined as the time from randomization to death from any cause or the first documented recurrence assessed by IRF, whichever occurred first.
Overall Survival (OS)	From baseline up to death due to any cause (up to approximately 64 months)	OS was defined as the time from randomization to death from any cause.
Investigator-assessed DFS in Participants With Tumor-Infiltrating Immune Cell (IC) 1/2/3	From baseline until first occurrence of DFS event (up to approximately 64 months)	Investigator assessed DFS for participants with PD-L1 expression of IC1/2/3 vs IC0, defined as the time from randomization to death from any cause or the first documented recurrence assessed by investigator, whichever occurred first. Investigator-assessed DFS was analyzed similarly to the analysis of IRF-assessed DFS. PD-L1 IC0 was defined as \<1% and IC1/2/3 was defined as \>=1% of tumor-infiltrating IC expressing PD-L1 as assessed by immunohistochemistry using SP142 assay. Recurrence was defined as any of the following: Local recurrence of renal cell carcinoma (RCC), new primary RCC, or distant metastasis of RCC.
IRF-assessed Event-free Survival (EFS)	From baseline until first documented recurrence event (up to approximately 64 months)	IRF-assessed EFS was defined as the time from randomization to death from any cause, or the first documented recurrence in participants without baseline disease by IRF or the first documented disease progression in participants identified as having baseline disease by IRF, whichever occurred first. Disease progression was defined as either unequivocal progression of baseline disease or new unequivocal lesions.
Disease-Specific Survival	From baseline up to death due to RCC (up to approximately 64 months)	Disease-specific survival was defined as the time from randomization to death from renal cell carcinoma (RCC).
IRF-assessed DFS in Participants With Tumor-Infiltrating IC 1/2/3	From baseline until first occurrence of DFS event (up to approximately 64 months)	IRF-assessed DFS was defined as the time from randomization to death from any cause or the first documented recurrence assessed by IRF, whichever occurred first. PD-L1 IC0 was defined as \<1% and IC1/2/3 was defined as \>=1% of tumor-infiltrating IC expressing PD-L1 as assessed by immunohistochemistry using SP142 assay.
Distant Metastasis-Free Survival	From baseline up to date of diagnosis of distant metastases or death due to any cause (up to approximately 64 months)	Distant metastasis-free survival, defined as the time from randomization to death from any cause or the date of diagnosis of distant (i.e., non-locoregional) metastases assessed by the investigator, whichever occurred first.
Percentage of Participants Who Are Alive and Investigator-assessed Recurrence Free at Year 1, 2, and 3	Up to 3 years	Investigator-assessed DFS rate was defined as the percentage of participants being alive and free of recurrence assessed by investigator at Year 1, 2, and 3 after randomization.
Percentage of Participants With Anti-Drug Antibodies (ADA) to Atezolizumab	Predose (hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)
Percentage of Participants Who Are Alive and IRF-assessed Recurrence Free at Year 1, 2, and 3	Up to 3 years	IRF-assessed DFS was defined as the percentage of participants being alive and free of recurrence assessed by IRF at Year 1, 2, and 3 after randomization.
Maximum Serum Concentration (Cmax) of Atezolizumab	Predose (Hour[hr]0), 0.5 hr after end of infusion (infusion duration=1 hr) on Cycle 1 Day 1; predose (hr 0) on Day 1 of Cycles 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)
Percentage of Participants With Adverse Events	From baseline up to death due to any cause (up to approximately 71 months)	An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unitended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a pharmaceutical product whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as a AEs.
Minimum Serum Concentration (Cmin) of Atezolizumab	Predose (Hour[hr]0), 0.5 hr after end of infusion (infusion duration=1 hr) on Cycle 1 Day 1; predose (hr 0) on Day 1 of Cycles 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)

Trial Locations

Locations (186): University of Texas Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Sunnybrook Odette Cancer Centre
🇨🇦
Toronto, Ontario, Canada
Princess Margaret Cancer Center
🇨🇦
Toronto, Ontario, Canada
Bradford Hill Centro de Investigaciones Clinicas
🇨🇱
Recoleta, Chile
Jiangsu Cancer Hospital
🇨🇳
Nanjing City, China
Urology Associates of Kingsport, P.C.
🇺🇸
Kingsport, Tennessee, United States
Hospital Aleman
🇦🇷
Caba, Argentina
Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU
🇦🇹
Salzburg, Austria
UZ Leuven Gasthuisberg
🇧🇪
Leuven, Belgium
Nagoya University Hospital
🇯🇵
Aichi, Japan
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
🇮🇹
Padova, Veneto, Italy
Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Urologie
🇩🇪
Dresden, Germany
Meir Medical Center; Oncology
🇮🇱
Kfar-Saba, Israel
Belinson Medical Center, Division of Oncology
🇮🇱
Petach Tikva, Israel
Tokyo Medical and Dental University Hospital
🇯🇵
Tokyo, Japan
Nippon Medical School Hospital
🇯🇵
Tokyo, Japan
Tokyo Women?s Medical University Adachi Medical Center
🇯🇵
Tokyo, Japan
Sint Franciscus Gasthuis; Inwendige Geneeskunde
🇳🇱
Rotterdam, Netherlands
St. Antonius locatie Leidsche Rijn
🇳🇱
Utrecht, Netherlands
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
🇵🇱
Kraków, Poland
Narodowy Inst.Onkol.im.Sk?odowskiej-Curie Pa?stw.Inst.Badawczy Kraków; Klinika Onkologii Klinicznej
🇵🇱
Kraków, Poland
UMC Radboud Nijmegen
🇳🇱
Nijmegen, Netherlands
Hospital Univ. Central de Asturias; Servicio de Oncologia
🇪🇸
Oviedo, Asturias, Spain
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli
🇵🇱
Lublin, Poland
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu; Oddzia? Chemioterapii
🇵🇱
Pozna?, Poland
Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
🇵🇱
Warszawa, Poland
Taichung Veterans General Hospital; Division of Urology
🇨🇳
Taichung, Taiwan
Chang Gung Medical Foundation-Linkou, Urinary Oncology
🇨🇳
Taoyuan, Taiwan
Clinic for Urology; Military Medical Academy
🇷🇸
Belgrade, Serbia
Trakya University Medical Faculty
🇹🇷
Edirne, Turkey
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷
Sihhiye/Ankara, Turkey
Zaporizhzhia Regional Clinic
🇺🇦
Zaporizhzhia, Ukraine
UCLA Urology; Urology
🇺🇸
Los Angeles, California, United States
The University of Chicago Biological Sciences; Dept. of Medicine, Section of Hematology/Oncology
🇺🇸
Chicago, Illinois, United States
Cleveland Clinic Foundation; Hematology and Oncology
🇺🇸
Cleveland, Ohio, United States
University of Tsukuba Hospital
🇯🇵
Ibaraki, Japan
Mie University Hospital
🇯🇵
Mie, Japan
Niigata University Medical & Dental Hospital
🇯🇵
Niigata, Japan
Cork Uni Hospital; Oncology Dept
🇮🇪
Cork, Ireland
Sourasky Medical Center; Oncology Department
🇮🇱
Tel-Aviv, Israel
Kyushu University Hospital
🇯🇵
Fukuoka, Japan
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
🇪🇸
Santiago de Compostela, LA Coruña, Spain
Asan Medical Center
🇰🇷
Seoul, Korea, Republic of
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸
Córdoba, Cordoba, Spain
Fakultni nemocnice Olomouc; Onkologicka klinika
🇨🇿
Olomouc, Czechia
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
🇮🇹
Bologna, Emilia-Romagna, Italy
Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
🇮🇪
Dublin, Ireland
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
Hospital Clínic i Provincial; Servicio de Oncología
🇪🇸
Barcelona, Spain
Rambam Health Care Campus; Oncology
🇮🇱
Haifa, Israel
Hadassah Ein Karem Hospital; Oncology Dept
🇮🇱
Jerusalem, Israel
Okayama University Hospital
🇯🇵
Okayama, Japan
VU Medisch Centrum; VU University Medical Center
🇳🇱
Amsterdam, Netherlands
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
🇳🇱
Amsterdam, Netherlands
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸
Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸
Madrid, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸
Madrid, Spain
P.A. Herzen Oncological Inst. ; Oncology
🇷🇺
Moscow, Moskovskaja Oblast, Russian Federation
City Clinical Oncology Hospital
🇷🇺
Moscow, Moskovskaja Oblast, Russian Federation
Oncology Institute of Vojvodina
🇷🇸
Sremska Kamenica, Serbia
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸
Madrid, Spain
Leicester Royal Infirmary
🇬🇧
Leicester, United Kingdom
Gazi University Medical Faculty; Department of ?nternal Medicine
🇹🇷
Ankara, Turkey
Lviv Com. City Clinical Hospital #8; Cardiol.Dept. for Pat. with Myocard.Infarction
🇺🇦
Lviv, Ukraine
TAIPEI VETERANS GENERAL HOSPITAL, Urology
🇨🇳
Taipei, Taiwan
Weston Park Hospital
🇬🇧
Sheffield, United Kingdom
China Medical University Hospital; Urology
🇨🇳
Taichung, Taiwan
Division of Urological surgery; Department of surgery, Chulalongkorn University
🇹🇭
Bangkok, Thailand
Ankara Uni School of Medicine; Medical Oncology
🇹🇷
Ankara, Turkey
CI Dnipropetrovsk CMCH #4 MA of MOHU Ch of Oncology and MR
🇺🇦
Dnipropetrovsk, Ukraine
Singleton Hospital; Pharmacy Department
🇬🇧
Swansea, United Kingdom
University of Oklahoma; Stephenson Oklahoma Canc Ctr
🇺🇸
Oklahoma City, Oklahoma, United States
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
🇮🇹
Meldola, Emilia-Romagna, Italy
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
🇮🇹
Milano, Lombardia, Italy
Fondazione IRCCS Policlinico San Matteo, Oncologia
🇮🇹
Pavia, Lombardia, Italy
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
🇮🇹
Arezzo, Toscana, Italy
Oregon Health & Science Uni
🇺🇸
Portland, Oregon, United States
CHU Henri Mondor; Service d'Oncologie Medicale
🇫🇷
Creteil, France
Institut Catala d Oncologia Hospital Duran i Reynals
🇪🇸
Barcelona, Spain
University of Florida
🇺🇸
Gainesville, Florida, United States
Royal Brisbane & Women's Hosp; Cancer Care Serv
🇦🇺
Herston, Queensland, Australia
City of Hope National Medical Center
🇺🇸
Duarte, California, United States
University of Colorado Cancer Center
🇺🇸
Aurora, Colorado, United States
Mayo Clinic - Rochester
🇺🇸
Rochester, Minnesota, United States
CHU de Nantes - Hotel Dieu
🇫🇷
Nantes, France
Aarhus Universitetshospital; Kræftafdelingen
🇩🇰
Aarhus N, Denmark
Mayo Clinic- Scottsdale
🇺🇸
Scottsdale, Arizona, United States
City of Hope, Antelope Valley
🇺🇸
Lancaster, California, United States
University of California Irvine Medical Center
🇺🇸
Orange, California, United States
City of Hope-South Pasadena
🇺🇸
South Pasadena, California, United States
City of Hope; Upland
🇺🇸
Upland, California, United States
Florida Cancer Specialists-Broadway, Fort Myers
🇺🇸
Fort Myers, Florida, United States
Univ of Miami, School of Med; Hem/Onc
🇺🇸
Miami, Florida, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Emory Uni - Winship Cancer Center; Hematology/Oncology
🇺🇸
Atlanta, Georgia, United States
Loyola University Medical Center, Cardinal Bernardin Cancer Center
🇺🇸
Maywood, Illinois, United States
Chesapeake Urology Research Associates
🇺🇸
Towson, Maryland, United States
Garden State Urology
🇺🇸
Whippany, New Jersey, United States
New York Oncology Hematology at Albany Medical Center
🇺🇸
Albany, New York, United States
University of Rochester Medical Center; Urology
🇺🇸
Rochester, New York, United States
Bellevue Hospital
🇺🇸
New York, New York, United States
Mount SInai Medical Center
🇺🇸
New York, New York, United States
SUNY Upstate Medical University
🇺🇸
Syracuse, New York, United States
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
🇺🇸
New York, New York, United States
Levine Cancer Institute
🇺🇸
Charlotte, North Carolina, United States
Fairview Hospital; Cleveland Clinic Cancer Center
🇺🇸
Cleveland, Ohio, United States
Hillcrest Hospital; Hirsch Cancer Center
🇺🇸
Mayfield Heights, Ohio, United States
Fox Chase Cancer Center; Hematology/Oncology
🇺🇸
Philadelphia, Pennsylvania, United States
Sanford Cancer Cnt Onco Clinic
🇺🇸
Sioux Falls, South Dakota, United States
Erlanger Health Systems
🇺🇸
Chattanooga, Tennessee, United States
Hospital Britanico; Oncologia
🇦🇷
Buenos Aires, Argentina
University of Utah; Huntsman Cancer Hospital
🇺🇸
Salt Lake City, Utah, United States
West Virginia University Hospitals Inc
🇺🇸
Morgantown, West Virginia, United States
Centro Oncologico Riojano Integral (CORI)
🇦🇷
La Rioja, Argentina
Calvary Mater Newcastle; Medical Oncology
🇦🇺
Waratah, New South Wales, Australia
Ashford Cancer Center Research
🇦🇺
Kurralta Park, South Australia, Australia
Austin Hospital; Medical Oncology
🇦🇺
Heidelberg, Victoria, Australia
Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie
🇦🇹
Linz, Austria
Hospital das Clinicas - UFRGS
🇧🇷
Porto Alegre, RS, Brazil
Hospital Erasto Gaertner
🇧🇷
Curitiba, PR, Brazil
Cliniques Universitaires St-Luc
🇧🇪
Bruxelles, Belgium
Instituto do Cancer do Estado de Sao Paulo - ICESP
🇧🇷
Sao Paulo, SP, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷
Porto Alegre, RS, Brazil
Tom Baker Cancer Centre-Calgary
🇨🇦
Calgary, Alberta, Canada
Hospital Alemao Oswaldo Cruz
🇧🇷
Sao Paulo, SP, Brazil
Cross Cancer Institute
🇨🇦
Edmonton, Alberta, Canada
The Ottawa Hospital Cancer Centre; Oncology
🇨🇦
Ottawa, Ontario, Canada
North York General Hospital; Inpatient Pharmacy
🇨🇦
Toronto, Ontario, Canada
McGill University Health Centre - Glen Site
🇨🇦
Montreal, Quebec, Canada
Centre Hospitalier universitaire de Québec/ Hotel Dieu de Québec
🇨🇦
Quebec, Canada
Sociedad de Investigaciones Medicas Ltda (SIM)
🇨🇱
Temuco, Chile
ONCOCENTRO APYS; Oncología
🇨🇱
Vina Del Mar, Chile
Fudan University Shanghai Cancer Center; Medical Oncology
🇨🇳
Shanghai City, China
Masarykuv onkologicky ustav
🇨🇿
Brno, Czechia
General University Hospital; CLINIC OF ONCOLOGY
🇨🇿
Praha 2, Czechia
Thomayerova nemocnice
🇨🇿
Praha 4 - Krc, Czechia
Herlev Hospital; Afdeling for Kræftbehandling
🇩🇰
Herlev, Denmark
CHU d'Angers
🇫🇷
Angers, France
Institut Mutualiste Montsouris; Oncologie
🇫🇷
Paris, France
CHU Pontchaillou
🇫🇷
Rennes, France
Nouvel Hopital Civil - CHU Strasbourg; Urologie
🇫🇷
Strasbourg, France
CHU de Rouen - Hôpital Charles Nicolle
🇫🇷
Rouen, France
Institut Gustave Roussy
🇫🇷
Villejuif, France
Medizinische Hochschule Hannover; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie
🇩🇪
Hannover, Germany
Universitätsklinikum des Saarlandes; Klinik für Urologie und Kinderurologie
🇩🇪
Homburg/Saar, Germany
Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
🇩🇪
München, Germany
Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen
🇩🇪
Heidelberg, Germany
Universitätsklinikum Tübingen; Klinik für Urologie
🇩🇪
Tübingen, Germany
National Cancer Center
🇰🇷
Goyang-si, Korea, Republic of
Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4
🇺🇦
Kharkiv, Kharkiv Governorate, Ukraine
Christie Hospital
🇬🇧
Manchester, United Kingdom
Royal Free Hospital
🇬🇧
London, United Kingdom
Freeman Hospital
🇬🇧
Newcastle upon Tyne, United Kingdom
MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Queen Elizabeth II Health Sciences Centre; Oncology
🇨🇦
Halifax, Nova Scotia, Canada
Kobe University Hospital
🇯🇵
Hyogo, Japan
Medizinische Universität Wien; Universitätsklinik für Urologie, Arbeitsgruppe Nierenzellkarzinome
🇦🇹
Wien, Austria
Sarah Cannon Research Institute
🇺🇸
Nashville, Tennessee, United States
Vanderbilt University Medical Center; Vanderbilt University
🇺🇸
Nashville, Tennessee, United States
Soroka Medical Center; Oncology Dept
🇮🇱
Beer Sheva, Israel
Chaim Sheba medical center, Oncology division
🇮🇱
Ramat Gan, Israel
BC Cancer ? Kelowna (Sindi Ahluwalia Hawkins Centre)
🇨🇦
Kelowna, British Columbia, Canada
Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont
🇨🇦
Sherbrooke, Quebec, Canada
Hirosaki University Hospital
🇯🇵
Aomori, Japan
Jichi Medical University Hospital
🇯🇵
Tochigi, Japan
Tokushima University Hospital
🇯🇵
Tokushima, Japan
Toranomon Hospital
🇯🇵
Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵
Tokyo, Japan
Keio University Hospital
🇯🇵
Tokyo, Japan
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
🇵🇱
Wroclaw, Poland
Altai Region Oncology Dispensory; Oncology
🇷🇺
Barnaul, Altaj, Russian Federation
Clinic for Urology, Clinical Center of Serbia; Clinic for Urology
🇷🇸
Belgrade, Serbia
Privolzhsk Regional Medical Center
🇷🇺
Nizhny Novgorod, Niznij Novgorod, Russian Federation
City Clinical Oncology Dispensary
🇷🇺
Saint-Petersburg, Sankt Petersburg, Russian Federation
Sverdlovsk Regional Clinical Hospital 1
🇷🇺
Yekaterinburg, Sverdlovsk, Russian Federation
Maharaj Nakorn Chiangmai Hospital; Department of Surgery/ Urology unit
🇹🇭
Chiangmai, Thailand
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
🇹🇷
Adana, Turkey
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
🇺🇦
Sumy, Ukraine
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸
Sant Andreu de La Barca, Barcelona, Spain
National Taiwan University Hospital, Department of Urology
🇨🇳
Taipei, Taiwan
Norton Cancer Institute
🇺🇸
Louisville, Kentucky, United States
Ochsner Clinic Foundation
🇺🇸
New Orleans, Louisiana, United States
Tulane Uni Health Sciences Center
🇺🇸
New Orleans, Louisiana, United States
Yale School of Medicine
🇺🇸
New Haven, Connecticut, United States
University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
A.O. Universitaria Policlinico Di Modena; Oncologia
🇮🇹
Modena, Emilia-Romagna, Italy